Table 1.
Incidence of adverse events in 13 patients.
| Adverse events | n (%) | ||
|---|---|---|---|
| Grade ≥ 3 | |||
| Any grade | Grade 3 | Grade 4 | |
| Hematologic toxicity | |||
| Leukocytopenia | 13 (100) | 8 (61.5) | 5 (38.5) |
| Neutropenia | 13 (100) | 12 (92.3) | |
| Febrile neutropenia | 1 (7.7) | 1 (7.7) | |
| Anemia | 9 (69.2) | 2 (15.4) | |
| Non-hematologic toxicity | |||
| Diarrhea | 5 (38.5) | 1 (7.7) | |
| Pulmonary edema | 1 (7.7) | 1 (7.7) | |
| Hypertension | 2 (15.4) | 2 (15.4) | |
| Syncope | 1 (7.7) | 1 (7.7) | |
| Urinary tract obstruction | 1 (7.7) | 1 (7.7) | |
| Mucocutaneous infection | 11 (84.6) | 2 (15.4) | |
| Arthralgia | 1 (7.7) | 1 (7.7) | |
| Grade 1/2* (*reported in ≥20% of patients) | |||
| Alopecia | 10 (76.9) | ||
| Rash | 5 (38.5) | ||
| Nausea | 6 (46.2) | ||
| Gastralgia/gastritis | 5 (38.5) | ||
| Constipation | 4 (30.8) | ||
| Hypoalbuminemia | 11 (84.6) | ||
| Anorexia | 4 (30.8) | ||
| Pyrexia | 3 (23.1) | ||
| Peripheral edema | 3 (23.1) | ||
| Weight increased | 5 (38.5) | ||
| Aspartate aminotransferase increased | 4 (30.8) | ||
| Peripheral neuropathy | 6 (46.2) | ||
| Upper respiratory infection | 7 (53.8) | ||
| Pneumonitis | 3 (23.1) | ||